An interventional study of High-touch strategy in Lung Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 48 under way, 2 of them phase 3. Lung Neoplasms · M.D. Anderson Cancer Center.
Among the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, this one is the 3rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 with no phase, reaches primary completion later than 47 of the 47 other live ones, and was the 162nd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →22 of the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18–50
M.D. Anderson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 68 · Phase 3 6 · Phase 4 1
First in 1993; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 40 across the 125 interventional studies, 127 across the 37 observational. Of the 99 that completed or were terminated, 38 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
20 of the studies in Lung Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
| NCT02596490M.D. Anderson Cancer CenterCouple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners | 2026-12-01 |
| NCT04516070M.D. Anderson Cancer CenterStereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis | 2026-12-31 |
| NCT04771520M.D. Anderson Cancer CenterAvapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this research study is to compare two different ways to increase lung cancer screening rates for tobacco quitline clients.
Primary Objective/Aim:
Aim 1. Compare two dissemination strategies that vary in intensity on demand for LCS. We hypothesize that there will be a higher demand for LCS in the high-touch strategy arm compared to the low-touch strategy arm, as demonstrated by self-reported LCS completion, as well as scheduling a visit with a health care provider to discuss LCS.
Secondary Objectives/Aim:
Aim 2. Evaluate the impact on reach of the high-touch and low-touch strategies to disseminate LCS educational materials (i.e., view of the decision aid or participation in a decision coaching visit). We expect that disseminating the LCS educational materials through the high-touch strategy will result in higher reach than delivering the LCS educational materials through the low-touch strategy.
Aim 3. Evaluate the financial sustainability and cost-effectiveness of the two approaches of disseminating LCS educational materials. We expect that the high-touch strategy will require a greater financial commitment and stronger partnerships between quitline service providers, state department of health, and health care systems, it will be a cost-effective dissemination strategy compared to the low-touch strategy (emailing/texting).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Quitline Client
Quitline client participants must meet the criteria for LCS with regards to age (50 to 80 years) and smoking history (20+ pack-years). This project will not re-confirm quitline client participant eligibility for screening. Tobacco treatment specialists will elicit study interest from only eligible quitline clients.
Representative of the Quitline Community
Representative of the Quitline Community will include any employee of the quitline service provider, representative from an organization that collaborates or funds a tobacco quitline, and/or a representative of the state department of health. All individuals will be adults (18 years and older) and able to speak English.
Representative of the Healthcare Sector
Representative of the healthcare sector will include any adult who works in healthcare, including but not limited to physicians, healthcare administrative leaders/managers, nurses, advanced practice providers. All individuals will be adults (18 years and older) and able to speak English.
Exclusion Criteria:
Not applicable as our focus on quitline clients and representatives (adults) of the quitline community or the healthcare sector.
Investigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients.
Behavioral: High-touch strategy
Investigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients.
Behavioral: High-touch strategy
Participants will receive the LCS educational materials, decision coaching call for the SDM visit, and navigation for LCS.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Time frame: Through study completion; an average of 1 year
Started Nov 2026 (actual). Primary completion is estimated for Jun 2032, 67 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 67 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
Start moved once since we started tracking on Sep 25, 2026: Jan 2027 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.